Drug/Small Molecule:
mazindol

2D structure

Overview

Trade Names: DEA No. 1605; Dimagrir; Magrilon; Mazanor; Mazildene; Mazindol [USAN:BAN:INN]; Mazindolum [INN-Latin]; Sanorex; Terenac; Teronac
PharmGKB Accession Id: PA450326

Description

Tricyclic anorexigenic agent unrelated to and less toxic than amphetamine, but with some similar side effects. It inhibits uptake of catecholamines and blocks the binding of cocaine to the dopamine uptake transporter. PubChem (source: Drug Bank)

Indication

Used in short-term (a few weeks) treatment of exogenous obesity in conjunction with a regimen of weight reduction based on caloric restriction, exercise, and behavior modification in patients with a body mass index of 30 kg of body weight per height in meters squared (kg/m<sup>2</sup>) or in patients with a body mass index of 27 kg/m<sup>2</sup> in the presence of risk factors such as hypertension, diabetes, or hyperlipidemia. (source: Drug Bank)

ATC Therapeutic Category

  • A08AA:Centrally acting antiobesity products

Pharmacology, Interactions, and Contraindications

Mechanism Of Action

Although the mechanism of action of the sympathomimetics in the treatment of obesity is not fully known, these medications have pharmacological effects similar to those of amphetamines. Unlike other sympathomimetic appetite suppressants such as phentermine, mazindol is thought to inhibit the reuptake of norepinephrine rather than to cause its release. (source: Drug Bank)

Pharmacology

Mazindol is a sympathomimetic amine, which is similar to an amphetamine. Mazindol stimulates the central nervous system (nerves and brain), which increases your heart rate and blood pressure and decreases your appetite. Sympathomimetic appetite suppressants are used in the short-term treatment of obesity. Their appetite-reducing effect tends to decrease after a few weeks. Because of this, these medicines are useful only during the first few weeks of a weight-loss program. (source: Drug Bank)

Food Interactions

If product causes GI problems, it can be taken during meals.
May be taken without regard to meals, but preferably 1 hour before a meal. (source: Drug Bank)

Absorption, Distribution, Metabolism, Elimination & Toxicity

Biotransformation

Hepatic. (source: Drug Bank)

Toxicity

Symptoms of a mazindol overdose include restlessness, tremor, rapid breathing, confusion, hallucinations, panic, aggressiveness, nausea, vomiting, diarrhea, an irregular heartbeat, and seizures. (source: Drug Bank)

Isomeric SMILES Code:

C1C[N@]2C(=N1)C3=CC=CC=C3[C@]2(C4=CC=C(C=C4)Cl)O (source: Drug Bank)

A list of non-curated publications that mention this drug along with other genes is available.

Drug Targets

Gene Description
SLC6A3 Uncurated Annotation (source: Drug Bank)
SLC6A2 Uncurated Annotation (source: Drug Bank)

A list of non-curated publications that mention this drug along with other drugs is available.

Drug Interactions

Drug Description
chlorpromazine Uncurated Annotation Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank)
ethopropazine Uncurated Annotation Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank)
fluoxetine Uncurated Annotation Risk of serotoninergic syndrome (source: Drug Bank)
fluphenazine Uncurated Annotation Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank)
fluvoxamine Uncurated Annotation Risk of serotoninergic syndrome (source: Drug Bank)
guanethidine Uncurated Annotation The agent decreases the effect of guanethidine (source: Drug Bank)
isocarboxazid Uncurated Annotation Possible hypertensive crisis (source: Drug Bank)
mesoridazine Uncurated Annotation Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank)
paroxetine Uncurated Annotation Risk of serotoninergic syndrome (source: Drug Bank)
perphenazine Uncurated Annotation Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank)
phenelzine Uncurated Annotation Possible hypertensive crisis (source: Drug Bank)
prochlorperazine Uncurated Annotation Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank)
promazine Uncurated Annotation Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank)
promethazine Uncurated Annotation Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank)
thioridazine Uncurated Annotation Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank)
tranylcypromine Uncurated Annotation Possible hypertensive crisis (source: Drug Bank)
trifluoperazine Uncurated Annotation Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank)
triflupromazine Uncurated Annotation Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank)
venlafaxine Uncurated Annotation Risk of serotoninergic syndrome (source: Drug Bank)

Non-Curated Information

A list of non-curated publications that mention this drug along with other diseases is available.

LinkOuts

Web Resource:
Wikipedia
DrugBank:
DB00579
KEGG Drug ID:
D00367
PubChem Compound ID:
4020
PubChem Substance ID:
7847433

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Non-Curated Publications

A list of non-curated publications that mention this drug is available.

PharmGKB integrates drug information from different sources: DrugBank, Open Eye Scientific Software.
Add New Alternate Name
Add New ATC Term
Add Cross Reference
Add a metabolite
Add a text annotation
Add a drug target
hint: enter a gene
    Add a drug interaction
    hint: enter a drug
    PharmGKB® is a registered trademark of HHS and is financially supported by NIH/NIGMS. It is managed at Stanford University (GM61374).
    ©2001-2010 PharmGKB.